Elanco Expands Pet Biologics With Strategic VETmAb Acquisition, Targeting $200M Growth
Elanco’s acquisition of VETmAb Biosciences boosts its veterinary biologics lineup, adding proven monoclonal antibody therapies to capture growing pet‑health demand.
3 minutes to read
